Radioactive Iodine Therapy
Use risk stratification to guide treatment of papillary thyroid microcarcinomas
Rather than tumor size alone, the American Thyroid Association’s risk stratification system should be used when assessing papillary thyroid microcarcinomas, according to data published in The Journal of Clinical Endocrinology & Metabolism.
Major adverse CV event risk lower after surgery, radioactive iodine for hyperthyroidism
Adults with hyperthyroidism who undergo surgery or receive radioactive iodine therapy have a lower risk for major adverse cardiovascular events than those receiving antithyroid drugs, according to data published in JAMA Network Open.
BLOG: My patients, my heroes: ‘Doug, get your thyroid checked’
In an afternoon Middle Clinical Experience teaching session, in the fall of 2018, I was sitting in the corner of the exam room watching the two students interviewing the simulated patient.
Thyroid dysfunction after radioiodine therapy common with Graves’ disease
Among adults with Graves’ disease, thyroid dysfunction was common and often recurrent during the first 12 months after radioiodine treatment, according to findings from the PRAGMA study.
Radioactive iodine use for thyroid cancer treatment falls after 2015 ATA guidelines update
From 2000 to 2018, use of radioactive iodine therapy in papillary thyroid cancer treatment greatly declined in favor of total thyroidectomy alone without radioactive iodine or lobectomy, according to study data.
Male sex, low free T4 risk factors for liver dysfunction with radioactive iodine therapy
Among adults who undergo radioactive iodine therapy for differentiated thyroid cancer, risk for hepatic dysfunction is elevated for men and all with low free thyroxine or high triglycerides, according to study data.
Increased cancer risk observed decades after radioactive iodine treatment
Young adults who received radioactive iodine therapy for differentiated thyroid cancer were at 92% increased risk for leukemia and 23% increased risk for any solid malignancies vs. those who did not receive radioactive iodine therapy.
Thyroidectomy as first-line treatment for Graves’ disease reduces mortality, CVD risk
Adults who underwent a thyroidectomy as first-line treatment for Graves’ disease had lower risks for all-cause mortality and cardiovascular disease than those treated with antithyroid drugs or radioactive iodine, according to study data.
Total thyroidectomy decreases thyrotropin receptor antibodies quicker in Graves’ disease
Changes in thyrotropin-binding inhibitory immunoglobulin levels for people with refractory Graves’ disease differed for those undergoing total thyroidectomy vs. radioactive iodine therapy, according to study data.
BLOG: The thyroid ‘supermoon’
For my inaugural post for this blog in November 2016, I wrote about the spectacular sight of the closest full supermoon since January 1948. It was a special occasion for me, generally and personally.